GRAIL, LLC experienced a notable increase in its stock price, primarily driven by positive developments surrounding its multi-cancer early detection test, Galleri.
GRAIL, LLC (NASDAQ:GRAL) saw its stock rise by 4.52% in yesterday's session, closing at CA$132.63. This uptick can be attributed to favorable news regarding the company's Galleri test, which received a positive endorsement from a panel of FDA advisors.
Advertisement
GRAIL, LLC
GRAL.US
GRAL.US
GRAIL, LLC
WealthAwesomeMarket cap
$5.92B
52W high
$134.42
52W low
$41.50
1W change
+22.84%
Beta
3.25
Analyst Price Targets
Based on 4 analysts covering GRAL · as of Sep 29, 2026
Wall Street analysts forecast GRAL stock price to fall 26.6% over the next 12 months.
Consensus
Buy3.50 / 5.00
Avg. Target
C$97.40
-26.6% Upside
Previously C$90.40 on Sep 28, 2026
Current Price
C$132.63
Last close
Analyst Breakdown (4 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GRAL's historical volatility
30-Day Vol
99.5%
Annualized
90-Day Vol
88.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$158.56
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$140.76 | C$99.85 – C$198.44 |
| 60 trading days | C$149.40 | C$91.93 – C$242.80 |
| 90 trading days | C$158.56 | C$87.48 – C$287.40 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors reacted positively to the FDA panel's endorsement, indicating a potential for broader insurance coverage and market acceptance of GRAIL's innovative cancer detection technology.
4.52%
GRAIL's stock performance reflects growing investor optimism about the future of its cancer detection technology following FDA panel support.
Bull case
The FDA panel's recommendation suggests a strong chance of approval for the Galleri test. If Medicare and private insurance start covering it, we could see a significant boost in sales and market presence for GRAIL.
Bear case
Despite the positive news, there are still concerns about the test's accuracy. Issues like false positives or negatives could slow down its adoption and shake investor confidence.
FDA Panel Endorsement
Advertisement
The recent vote by the FDA's Molecular and Clinical Genetics Panel showed reasonable evidence supporting the effectiveness of GRAIL's Galleri test. The panel voted 6-4 in favor of its efficacy and unanimously agreed on its safety. This endorsement could pave the way for Medicare and private insurance coverage, significantly enhancing the test's market potential.
Market Reaction
Following the FDA panel's positive assessment, GRAIL's stock saw a notable uptick. Investors are optimistic that the endorsement will lead to broader acceptance of the Galleri test, which is currently available only through cash payment. The potential for insurance coverage could dramatically increase the test's accessibility and sales.
Future Considerations
While the endorsement is a significant milestone for GRAIL, investors should remain cautious. Concerns about the test's accuracy and the need for it to complement existing screening methods may affect its adoption. As the FDA decision approaches in 2027, market sentiment will likely fluctuate based on ongoing developments.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
